BVF as of Dec. 31, 2017
Portfolio Holdings for BVF
BVF holds 43 positions in its portfolio as reported in the December 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Array BioPharma | 13.4 | $111M | 8.7M | 12.80 | |
| Anaptysbio Inc Common (ANAB) | 7.2 | $60M | 594k | 100.72 | |
| Blueprint Medicines (BPMC) | 7.0 | $58M | 767k | 75.41 | |
| Xoma Corp Del (XOMA) | 6.5 | $54M | 1.5M | 35.60 | |
| Concert Pharmaceuticals I equity | 6.1 | $51M | 2.0M | 25.87 | |
| Cytokinetics (CYTK) | 5.6 | $47M | 5.7M | 8.15 | |
| Chemocentryx | 5.4 | $45M | 7.6M | 5.95 | |
| Biolinerx Ltd-spons | 3.4 | $28M | 26M | 1.09 | |
| Syndax Pharmaceuticals (SNDX) | 3.4 | $28M | 3.2M | 8.76 | |
| ArQule | 3.3 | $27M | 16M | 1.65 | |
| Cytomx Therapeutics (CTMX) | 2.9 | $24M | 1.1M | 21.11 | |
| Cti Biopharma | 2.8 | $23M | 8.6M | 2.68 | |
| Kura Oncology (KURA) | 2.5 | $21M | 1.4M | 15.30 | |
| Infinity Pharmaceuticals (INFIQ) | 2.4 | $20M | 9.8M | 2.03 | |
| Pieris Pharmaceuticals (PIRS) | 2.4 | $20M | 2.6M | 7.55 | |
| Oncomed Pharmaceuticals | 2.1 | $18M | 4.3M | 4.10 | |
| Regulus Therapeutics | 1.8 | $15M | 14M | 1.04 | |
| Gtx Inc Del | 1.7 | $14M | 1.1M | 12.71 | |
| Erytech Pharma Sa | 1.7 | $14M | 625k | 22.02 | |
| Vbi Vaccines | 1.6 | $13M | 3.1M | 4.27 | |
| Forward Pharma A/s | 1.5 | $13M | 3.5M | 3.66 | |
| Spero Therapeutics (SPRO) | 1.5 | $12M | 1.0M | 11.75 | |
| Cascadian Therapeutics | 1.4 | $12M | 3.1M | 3.70 | |
| Spring Bk Pharmaceuticals In | 1.3 | $11M | 824k | 13.45 | |
| Xenon Pharmaceuticals (XENE) | 1.2 | $10M | 3.6M | 2.82 | |
| Glycomimetics (GLYC) | 1.0 | $8.4M | 498k | 16.79 | |
| Sunesis Pharmaceuticals Inc Ne | 0.9 | $7.5M | 2.0M | 3.69 | |
| Alpine Immune Sciences (ALPN) | 0.9 | $7.6M | 676k | 11.20 | |
| Molecular Templates | 0.9 | $7.3M | 724k | 10.02 | |
| Verastem | 0.8 | $6.9M | 2.3M | 3.07 | |
| Protagonist Therapeutics (PTGX) | 0.7 | $6.1M | 294k | 20.80 | |
| Immune Design | 0.7 | $5.7M | 1.5M | 3.90 | |
| Tocagen | 0.7 | $5.7M | 557k | 10.25 | |
| Corvus Pharmaceuticals (CRVS) | 0.6 | $4.8M | 459k | 10.36 | |
| Achillion Pharmaceuticals | 0.6 | $4.6M | 1.6M | 2.88 | |
| Intra Cellular Therapies (ITCI) | 0.5 | $4.0M | 273k | 14.48 | |
| Contrafect | 0.4 | $3.5M | 3.5M | 1.01 | |
| Orexigen Therapeutics Inc. 144a 2 3/4% Due 12/1/2020 Jd1 note 2.750%12/0 | 0.4 | $3.6M | 10M | 0.36 | |
| Vical | 0.3 | $2.6M | 1.4M | 1.83 | |
| Anthera Pharmaceuticals (ANTH) | 0.2 | $2.0M | 1.2M | 1.65 | |
| Pain Therapeutics | 0.2 | $1.3M | 326k | 4.00 | |
| Orexigen Therapeutics | 0.1 | $948k | 735k | 1.29 | |
| Loxo Oncology | 0.0 | $369k | 4.4k | 84.13 |
